Similarly, Met-RANTES, a chemokines receptor antagonist (CCR5), in Fisher-to-Lewis allografts, blocked the effects of RANTES (regulated on activation, normal T-cell expressed) reducing the infiltration of lymphocytes and macrophages in allografts, accompanied by decreased mRNA expression of interleukin (IL)-2, IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), and RANTES and thereby reduced glomerulosclerosis, tubulointerstitial fibrosis, and proteinuria [50]. The gene discussed is CCL5; the disease is glomerulosclerosis.